Costimulatory and Checkpoint Modulation
Petrov et al. demonstrated reduced CD80 expression on M1-like monocytes in ME/CFS, in contrast to elevated CD80 in long COVID β suggesting impaired costimulatory capacity specific to ME/CFS (Petrov et al. 2026). Combined with existing evidence for PD-1/PD-L1 checkpoint dysregulation in ME/CFS (Iu et al. 2024), this points to a potential dual deficit in T cell activation (low costimulation + active checkpoint inhibition). However, both features could be downstream consequences of a single upstream mechanism β chronic antigen stimulation, monocyte exhaustion, or epigenetic reprogramming β rather than independent targets requiring separate interventions. Therapeutic approaches that target CD80 or PD-1 directly must also contend with the unresolved question whether CD80 suppression is adaptive or maladaptive (see Open Questions below).
Certainty: 0.20. CD80 provides the essential second signal for T cell activation via CD28. Without adequate costimulation, T cells encountering antigen become anergic or tolerised rather than activated. CD28 superagonists (modified from the TGN1412 antibody family, with safety modifications following the 2006 cytokine storm event) could bypass deficient CD80 on monocytes and directly activate CD28 on T cells.
Critical immunological caveat: CD80-CTLA-4 axis omitted from simplified rationale. CD80 is a dual ligand: it binds both CD28 (costimulatory) AND CTLA-4 (inhibitory), with ~20-fold higher affinity for CTLA-4 than CD28. CD28 superagonist strategies that bypass CD80 lose the opportunity for CD80-CTLA-4 inhibitory engagement but could also fail to mimic the normal CD28/CTLA-4 balance. The net immunological effect of CD28 agonism without CD80-mediated CTLA-4 engagement is uncertain. Additionally, if CD80 suppression in ME/CFS is an adaptive protective mechanism (see Open Questions below), then restoring CD80 signaling β by any mechanism β could trigger autoimmune pathology, making the entire therapeutic rationale contingent on resolving the adaptive vs maladaptive question first.
Safety. CRITICAL: TGN1412 caused life-threatening cytokine release syndrome in 6 healthy volunteers in a 2006 Phase I trial β a seminal drug safety disaster. All 6 volunteers developed multi-organ failure within hours of infusion from a massive cytokine storm (IL-6, TNF-Ξ±, IFN-Ξ³). Modified versions (dose titration starting 1β2 orders of magnitude below the expected pharmacologically active dose, partial agonism, Fc-silent antibodies) are under investigation but NONE are approved for clinical use. This approach would require: + Confirmed CD80 deficiency on M1-like monocytes by flow cytometry before consideration + Intensive inpatient cytokine monitoring (IL-6, TNF-Ξ±, IFN-Ξ³ every 2β4 hours for 24 hours post-dose) + Prophylactic corticosteroid and anti-IL-6 receptor antibody availability + Exclusion of patients with any history of autoimmunity, elevated baseline cytokines, or POTS with tachycardia episodes (autonomic instability may compound hemodynamic risk) Given the catastrophic precedent of TGN1412 and the unresolved adaptive-vs-maladaptive question, this approach is currently suitable only as a research direction in in vitro models and should not be considered a therapeutic proposal without resolution of the CD80 tolerance question.
Testable prediction. In ex vivo co-culture, low-dose CD28 superagonist will restore ME/CFS monocyte-driven T cell proliferation without triggering supraphysiological cytokine release above 2x baseline; dose-response curves will identify a therapeutic window below the cytokine storm threshold.
Certainty: 0.20. Existing evidence shows PD-1/PD-L1 exhaustion in ME/CFS T cells, and Iu et al. documented PD-L1 upregulation on ME/CFS monocytes (Iu et al. 2024). CD80 suppression may represent an adaptive tolerance mechanism co-occurring with checkpoint-mediated exhaustion β together creating a profound T cell activation deficit. PD-1/PD-L1 inhibitors (nivolumab, pembrolizumab) could reverse exhaustion, but carry autoimmune adverse event risk that may be elevated in ME/CFS given documented autoantibody prevalence. CRITICAL: as with CD28 superagonists, this therapeutic rationale is contingent on CD80 suppression being maladaptive rather than adaptive. If CD80 suppression is protective (see Open Questions below), checkpoint inhibition could remove a necessary brake on autoimmunity, creating a risk profile for which no ME/CFS-specific safety data exist. No patient with ME/CFS has received checkpoint inhibitor therapy in a published study.
Safety. Checkpoint inhibitors cause immune-related adverse events (irAEs) in 15β40% of cancer patients, including potentially fatal colitis (10β15%), pneumonitis (3β5%), endocrinopathies (hypophysitis 5β10%, thyroiditis 10β20%), hepatitis (5β10%), and myocarditis (1β2%). ME/CFS patients may have ADDITIONAL susceptibility due to pre-existing immune dysregulation, autoantibody prevalence, and documented autoimmune comorbidity clustering. The proposed low-dose induction (20β40 mg flat dose vs standard 240 mg) has no evidence base in ME/CFS. This approach should be considered only in the context of a formal clinical trial with: + Confirmed PD-1+ CD8+ T cell exhaustion by flow cytometry and PD-L1+ monocytes + Exclusion of patients with pre-existing autoimmune antibodies (ANA, RF, anti-thyroid, anti-GPCR) + Weekly monitoring for colitis (diarrhoea, abdominal pain), pneumonitis (dyspnoea, cough), and endocrinopathy (fatigue, hypotension, electrolyte abnormalities) + Pre-specified stopping criteria: any Grade β₯ 2 irAE or new autoantibody seroconversion Current risk profile in ME/CFS is entirely unknown.
Testable prediction. Ex vivo PD-1 blockade will restore ME/CFS T cell proliferation to viral antigens only when combined with CD80 costimulation; checkpoint blockade alone will produce incomplete restoration, suggesting combined CD80 + PD-1 targeting is required β or alternatively, that neither target is addressable in isolation if CD80 suppression is adaptive.